Year All2024202320222021202020192018 December 16, 2024 Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 November 25, 2024 Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference November 18, 2024 Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain November 13, 2024 Contineum Therapeutics to Attend Upcoming Investor Conferences November 6, 2024 Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights August 28, 2024 Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences August 13, 2024 Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights July 31, 2024 Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis June 24, 2024 Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors June 4, 2024 Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference
December 16, 2024 Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
November 18, 2024 Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain
November 6, 2024 Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
August 13, 2024 Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
July 31, 2024 Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis
June 4, 2024 Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference
